

June 30, 2017



# **Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress**

ISNES, Belgium, June 30, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it will be presenting at the EuropaColon Advocacy Masterclass and will be exhibiting at the European Society for Medical Oncology Congress on Gastrointestinal Cancer (ESMO GI).

EuropaColon works with 43 groups across 32 European countries and has been recognised as the voice of colorectal cancer patients in Europe. The organisation's annual Advocacy Masterclass will be held in Barcelona, Spain from Thursday 29<sup>th</sup> June till Saturday 1<sup>st</sup> July, in partnership with ESMO GI. On Friday 30<sup>th</sup> June, Volition's Chief Scientific Officer, Dr. Jake Micallef, will present a talk at the masterclass entitled 'The future of screening'.

Dr. Micallef commented, 'It is great to be able to be part of this event and be a voice in the conversation. The future of screening is looking very positive, with companies such as Volition making steps towards tests which will be accessible, accurate and cost effective.'

ESMO GI is a global event related to the care of patients with gastrointestinal cancer. The event covers the processes of screening and diagnosis and is endorsed by leading bodies in the field. This will be the 19<sup>th</sup> World Congress. The location is Barcelona at The International Convention Centre of Barcelona. Further details of the event can be found at:

<http://worldgicancer.com/WCGI/index.asp>

## **About Volition**

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics<sup>®</sup>, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (<http://www.volitionrx.com>) or connect with us via:

Twitter: <https://twitter.com/volitionrx>

LinkedIn: <https://www.linkedin.com/company/volitionrx>

Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

## Media / Investor Contacts

Louise Day, Volition <a href="mailto:L.day@volitionrx.com">L.day@volitionrx.com</a> +44 (0)7557 774620	Scott Powell, Volition <a href="mailto:S.powell@volitionrx.com">S.powell@volitionrx.com</a> +1 (646) 650 1351
Tirth Patel, Edison Advisors <a href="mailto:tpatel@edisongroup.com">tpatel@edisongroup.com</a> +1 (646) 653 7035	Rachel Carroll, Edison Advisors <a href="mailto:rcarroll@edisongroup.com">rcarroll@edisongroup.com</a> +44 (0)20 3077 5711

## Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Q™ and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volition-to-present-at-the-europacoln-advocacy-masterclass-and--exhibit-at-the-european-society-for-medical-oncology-gastrointestinal-cancer-congress-300482475.html>

SOURCE VolitionRx Ltd